Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 Years of Age).
Conditions
Interventions
Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R
Investigational MenC-CRM adjuavnted with 25 ug of LHD153R
+3 more
Locations
1
Germany
GSK Investigational Site
Berlin, Germany
Start Date
March 1, 2016
Primary Completion Date
August 31, 2017
Completion Date
August 31, 2017
Last Updated
June 28, 2019
NCT04886154
NCT01939158
NCT01266993
NCT02451514
NCT02946385
NCT01900899
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions